Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BioDrugs
Published in: BioDrugs 3/2016

01-06-2016 | Adis Drug Evaluation

Shingles (Herpes Zoster) Vaccine (Zostavax®): A Review in the Prevention of Herpes Zoster and Postherpetic Neuralgia

Author: Gillian M. Keating

Published in: BioDrugs | Issue 3/2016

Login to get access

Abstract

Zostavax® is a live attenuated shingles (herpes zoster) vaccine approved in the EU for the prevention of herpes zoster (HZ) and postherpetic neuralgia (PHN) in adults aged ≥50 years. Zoster vaccine protected against HZ in adults aged 50–59 years (ZEST trial) and ≥60 years [Shingles Prevention Study (SPS)], and also reduced the burden of illness associated with HZ and the risk of PHN in adults aged ≥60 years (SPS). A large amount of real-world data also supports the efficacy of zoster vaccine. Results of the SPS Short- and Long-Term Persistence Substudies and real-world studies indicate that zoster vaccine provided continued benefit in the longer term, albeit with a gradual decline in vaccine efficacy over time; long-term effectiveness studies are ongoing. The need for a booster dose is still unknown, but a study showed that, if necessary, a booster dose administered to adults aged ≥70 years who received their first dose of zoster vaccine ≥10 years previously was immunogenic. Zoster vaccine had a favourable safety and tolerability profile, with the most commonly reported adverse events being non-severe injection-site reactions. In conclusion, zoster vaccine reduces the incidence of HZ and PHN, thereby reducing the burden of illness associated with HZ; improved uptake of zoster vaccine is needed.
Literature
1.
2.
Gater A, Uhart M, McCool R, et al. The humanistic, economic and societal burden of herpes zoster in Europe: a critical review. BMC Public Health. 2015;15:193.CrossRefPubMedPubMedCentral
3.
4.
Johnson RW, Alvarez-Pasquin M-J, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015;3(4):109–20.CrossRefPubMedPubMedCentral
5.
Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833.CrossRefPubMedPubMedCentral
6.
7.
Lang PO, Govind S, Bokum AT, et al. Immune senescence and vaccination in the elderly. Curr Top Med Chem. 2013;13(20):2541–50.CrossRefPubMed
8.
9.
10.
11.
12.
Paganino C, Alicino C, Trucchi C, et al. Herpes zoster: the rationale for the introduction of vaccination in Italy. J Prev Med Hyg. 2015;56(1):E33–6.PubMedPubMedCentral
13.
14.
Keating GM. Shingles (herpes zoster) vaccine (Zostavax®): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years. Drugs. 2013;73(11):1227–44.CrossRefPubMed
15.
Levin MJ, Schmader KE, Gnann JW, et al. Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. J Infect Dis. 2013;208(9):1386–90.CrossRefPubMedPubMedCentral
16.
Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197(6):825–35.CrossRefPubMedPubMedCentral
17.
Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis. 2009;200(7):1068–77.CrossRefPubMedPubMedCentral
18.
Levin MJ, Schmader KE, Pang L, et al. Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults. J Infect Dis. 2016;213:14–22.CrossRefPubMed
19.
Irwin MR, Levin MJ, Laudenslager ML, et al. Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications. Clin Infect Dis. 2013;56(8):1085–93.CrossRefPubMedPubMedCentral
20.
Diez-Domingo J, Weinke T, Garcia de Lomas J, et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial. Vaccine. 2015;33(6):789–95.CrossRefPubMed
21.
Mills R, Tyring SK, Levin MJ, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine. 2010;28(25):4204–9.CrossRefPubMed
22.
Russell AF, Parrino J, Fisher CL, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids. Vaccine. 2015;33(27):3129–34.CrossRefPubMed
23.
Guthridge JM, Cogman A, Merrill JT, et al. Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J Rheumatol. 2013;40(11):1875–80.CrossRefPubMed
24.
Hata A, Inoue F, Yamasaki M, et al. Safety, humoral and cell-mediated immune responses to herpes zoster vaccine in subjects with diabetes mellitus. J Infect. 2013;67(3):215–9.CrossRefPubMed
25.
Benson C, Hua L, Andersen J, et al. Zostavax is generally safe and immunogenic in HIV + adults virologically suppressed on ART: results of a phase 2, randomized, double-blind, placebo-controlled trial [abstract no. 96]. In: 19th Conference of retroviruses and opportunistic infections; 2012.
26.
Vermeulen JN, Lange JMA, Tyring SK, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine. 2012;30(5):904–10.CrossRefPubMed
27.
Vesikari T, Hardt R, Rümke HC, et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥70 years: a randomized study of a single dose vs. two different two-dose schedules. Hum Vaccines Immunother. 2013;9(4):858–64.
28.
Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc. 2007;55(10):1499–507.CrossRefPubMed
29.
MacIntyre CR, Egerton T, McCaughey M, et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old. Hum Vaccine. 2010;6(11):894–902.CrossRef
30.
Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis. 2012;54(7):922–8.CrossRefPubMedPubMedCentral
31.
Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.CrossRefPubMed
32.
33.
Schmader KE, Johnson GR, Saddier P, et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc. 2010;58(9):1634–41.CrossRefPubMedPubMedCentral
34.
Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy. Clin Infect Dis. 2012;55(10):1320–8.CrossRefPubMedPubMedCentral
35.
36.
Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011;305(2):160–6.CrossRefPubMed
37.
38.
Baxter R, Bartlett J, Hansen J, et al. Effectiveness of live zoster vaccine in preventing herpes zoster [abstract no. 1928 plus poster]. In: IDWeek 2015; 2015.
39.
Langan SM, Smeeth L, Margolis DJ, et al. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10(4):e1001420.CrossRefPubMedPubMedCentral
40.
Tseng HF, Chi M, Smith N, et al. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis. 2012;206(2):190–6.CrossRefPubMed
41.
Tseng HF, Smith N, Sy LS, et al. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine. 2011;29(20):3628–32.CrossRefPubMed
42.
Tseng HF, Lewin B, Hales CM, et al. Zoster vaccine and the risk of postherpetic neuralgia in patients who developed herpes zoster despite having received the zoster vaccine. J Infect Dis. 2015;212(8):1222–31.CrossRefPubMed
43.
Langan SM, Thomas SL, Smeeth L, et al. Zoster vaccination is associated with a reduction of zoster in elderly patients with chronic kidney disease. Nephrol Dial Transplant. 2016. doi:10.​1093/​ndt/​gfv432.PubMed
44.
Tseng HF, Luo Y, Shi J, et al. Effectiveness of herpes zoster vaccine in patients 60 years and older with end-stage renal disease. Clin Infect Dis. 2016;62(4):462–7.PubMed
45.
Tseng HF, Tartof S, Harpaz R, et al. Vaccination against zoster remains effective in older adults who later undergo chemotherapy. Clin Infect Dis. 2014;59(7):913–9.CrossRefPubMed
46.
Zhang J, Delzell E, Xie F, et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther. 2011;13(5):R174.CrossRefPubMedPubMedCentral
47.
Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308(1):43–9.CrossRefPubMedPubMedCentral
48.
Cheetham TC, Marcy SM, Tseng H-F, et al. Risk of herpes zoster and disseminated varicella zoster in patients taking immunosuppressant drugs at the time of zoster vaccination. Mayo Clin Proc. 2015;90(7):865–73.CrossRefPubMed
49.
Marin M, Yawn BP, Hales CM, et al. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Hum Vaccines Immunother. 2015;11(5):1157–64.CrossRef
50.
Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the Shingles Prevention Study: a randomized trial. Ann Intern Med. 2010;152(9):545–54.CrossRefPubMed
51.
Popmihajlov Z, Pang L, Brown E, et al. Low rates of severe injection-site and systemic adverse events within 7 days post-vaccination with ZOSTAVAX™, a post hoc analysis of two pivotal phase 3 trials [abstract no. 2383 plus poster]. In: 26th European Congress of Clinical Microbiology and Infectious Diseases; 2016.
52.
Morrison VA, Oxman MN, Levin MJ, et al. Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis. 2013;208(4):559–63.CrossRefPubMedPubMedCentral
53.
Lindsey S, Oufnac B, Walker H. Safety of zoster vaccination administration in rheumatic patients on current biologic therapy [abstract no. 1836]. Arthritis Rheumatol. 2014;66(Suppl 10):S806.
54.
Issa NC, Marty FM, Leblebjian H, et al. Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2014;20(2):285–7.CrossRefPubMed
55.
Tseng HF, Liu A, Sy L, et al. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. J Intern Med. 2012;271(5):510–20.CrossRefPubMed
56.
Baxter R, Tran TN, Hansen J, et al. Safety of Zostavax™: a cohort study in a managed care organization. Vaccine. 2012;30(47):6636–41.CrossRefPubMed
57.
Bresse X, Annemans L, Préaud E, et al. Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res. 2013;13(3):393–406.CrossRefPubMed
58.
Préaud E, Uhart M, Böhm K, et al. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany. Hum Vaccines Immunother. 2015;11(4):884–96.CrossRef
59.
Ultsch B, Weidemann F, Reinhold T, et al. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res. 2013;13:359.CrossRefPubMedPubMedCentral
60.
de Boer PT, Pouwels KB, Cox JM, et al. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine. 2013;31(9):1276–83.CrossRefPubMed
61.
Bilcke J, Marais C, Ogunjimi B, et al. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine. 2012;30(3):675–84.CrossRefPubMed
62.
63.
Li X, Zhang JH, Betts RF, et al. Modeling the durability of ZOSTAVAX® vaccine efficacy in people ≥60 years of age. Vaccine. 2015;33(12):1499–505.CrossRefPubMed
64.
65.
Esposito S, Bonanni P, Maggi S, et al. Recommended immunization schedules for adults: clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). Hum Vaccines Immunother. 2016. doi:10.​1080/​21645515.​2016.​1150396
66.
67.
Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96.CrossRefPubMed
68.
Oxman MN, Schmader KE. Zoster vaccine in immunocompromised patients: time to reconsider current recommendations. Clin Infect Dis. 2014;59(7):920–2.CrossRefPubMed
69.
Kanitz EE, Wu LA, Giambi C, et al. Variation in adult vaccination policies across Europe: an overview from VENICE network on vaccine recommendations, funding and coverage. Vaccine. 2012;30(35):5222–8.CrossRefPubMed
70.
Metadata
Title
Shingles (Herpes Zoster) Vaccine (Zostavax®): A Review in the Prevention of Herpes Zoster and Postherpetic Neuralgia
Author
Gillian M. Keating
Publication date
01-06-2016
Publisher
Springer International Publishing
Published in
BioDrugs / Issue 3/2016
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI
https://doi.org/10.1007/s40259-016-0180-7

Other articles of this Issue 3/2016

BioDrugs 3/2016 Go to the issue

Review Article

Update on Metastatic Uveal Melanoma: Progress and Challenges

Short Communication

Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab

Review Article

Assessing the Immunogenicity of Biopharmaceuticals

Short Communication

Anagrelide and Mutational Status in Essential Thrombocythemia

Systematic Review

Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis

Review Article

Future Therapeutics in Alzheimer’s Disease: Development Status of BACE Inhibitors